The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1551
July 16, 2018
View Complete Issue         Table of Contents 2019 
Firvanq - Vancomycin Oral Solution
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Firvanq - Vancomycin Oral Solution
July 16, 2018 (Issue: 1551)
The FDA has approved vancomycin oral solution (Firvanq – Cutis Pharma) for treatment of Clostridium difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Firvanq - Vancomycin Oral Solution
Article code: 1551d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.